• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 13.95
  • VXN 18.04
  • VXO -
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)

Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:

Indicator Windows:

Company Profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human disease, including immunology, metabolism, cardiology, and ophthalmology. The company?s drug candidates include LX1031, which has completed Phase II clinical trials for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX4211 that has completed Phase II clinical trials to treat type 2 diabetes; LX2931, which is in Phase II clinical trials for the treatment of rheumatoid arthritis and other autoimmune diseases; and LX1032 that has completed Phase II clinical trials to treat the symptoms associated with carcinoid syndrome. It also has a preclinical development drug candidate, LX7101, for the treatment of glaucoma. The company has drug discovery alliances with Bristol-Myers Squibb Company; Genentech, Inc.; N.V. Organon; and Takeda Pharmaceutical Company Limited. It also has drug development financing collaboration with Symphony Icon; collaboration agreement with Taconic Farms, Inc.; and an alliance with Nuevolution A/S, which provides access to Nuevolution?s Chemetics platform chemistry technology. The company was founded in 1995 and is headquartered in The Woodlands, Texas.

LXRX (Lexicon Pharmaceuticals Inc)
Last Trade 3.6183 Date 9/19/2019
Change % -4.79 % Price Change -0.19
Open 3.81 52 Week High 11.51
High 3.85 52 Week Low 1.125
Low 3.53 Type stock
Volume 539449 Average Volume 2004814
Prev Close 3.8 Stock Exchange NASDAQ
Bid 3.6 Ask 3.66
Bid Size 6 Ask Size 10
1st Yr Estimated EPS Growth 0.8452 2nd Yr Estimated EPS Growth -0.2903
2 Years Forward Earning Yield -0.2895 2 Years Forward PE Ratio
2 Years EV/Forward EBIT 2 Years EV/Forward EBITDA -5.4292
Book Value per Share -0.6106 Book Value Yield -0.1607
Buy Back Yield 0.0015 CAPE Ratio
Cash Return -0.1495 Cash Flow per Share -0.9604
Cash Flow Yield -0.2527 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield -0.2211 EV/EBIT
EV/EBITDA EV / Free Cash Flow
EV / Forward EBIT EV / Forward EBITDA -3.6195
EV / Forward Revenue 5.6555 EV / Pre Tax Income
EV / Revenue 12.6453 EV / Total Asset 2.3287
Expected Dividend Growth Rate Free Cash Flow per Share -0.9614
Free Caash Flow Ratio Free Cash Flow Yield -0.253
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield -0.4079 Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio Payout Ratio 0.0
PB Ratio PB Ratio 10 Year Growth
PB Ratio 3 Year Growth 16.513717 Cash Ratio 3 Year Average 455.7186
Price to Cash Flow Ratio PEG Payback
PEG Ratio PE Ratio
PE Ratio 10 Year Average PE Ratio 10 Year Growth
PE Ratio 10 Year High PE Ratio 10 Year Low
PE Ratio 1 Year Avg PE Ratio 1 Year High
PE Ratio 1 Year Low PE Ratio 3 Year Avg
PE Ratio 5 Year Avg PE Ratio 5 Year High
PE Ratio 5 Year Low Free Cash Flow Ratio 10 Year Growth
Free Cash Flow Ratio 3 Year Avg 11.546528 Price Change 1 Month 2.878788
Price to Cash Ratio 3.810575 Price / EBITDA
Price to Sales Ratio 9.384544 Price to Sales Ratio 10 Year Growth -0.048215
Price to Sales Ratio 3 Year Avg 12.118574 Price to Sales Ratio 5 Year Avg
Sale per Share 0.4049 Sales Yield 0.1066
Sustainable Growth Rate Tangible Book Value per Share -1.493
Tangible Book Value per Share 3 year Avg -0.1712 Tangible Book Value per Share 5 year Avg 0.0512
Total Asset per Share 2.1938 Total Yield 0.0015
Working Capital per Share 0.9409 Working Capital per Share 3 Year Avg 1.4087
Working Capital per Share 5 Year Avg 1.3871 Beta 1.3574